Teva To Pay Up To $70M To Settle With Pfizer
Under the terms of the settlement, Israel-based generics maker Teva will continue to sell its own generic version of both drugs and will have the option to sell a generic version of Pfizer’s cancer drug epirubicin in 2007, prior to the patent expiration date of August 2007.
Teva also agreed that it...
Already a subscriber? Click here to login